Accumulating evidence has shown that FGF2 signaling plays important roles in tumor lymphangiogenesis and lymph node metastasis,[26, 27, 28] and may serve as a promising therapeutic target for lymphatic metastatic cancer. This evidence concerns the gene FGF2 and neoplasm.